It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sestrin2 (SESN2) is a highly evolutionary conserved protein and involved in different cellular responses to various stresses. However, the potential function of SESN2 in immune system remains unclear. The present study was designed to test whether dendritic cells (DCs) could express SESN2, and investigate the underlying molecular mechanism as well as its potential significance. Herein, we firstly reported that SESN2 was expressed in DCs after high mobility group box-1 protein (HMGB1) stimulation and the apoptosis of DCs was obviously increased when SESN2 gene silenced by siRNA. Cells undergone SESN2-knockdown promoted endoplasmic reticulum (ER) stress (ERS)-related cell death, markedly exacerbated ER disruption as well as the formation of dilated and aggregated structures, and they significantly aggravated the extent of ERS response. Conversely, overexpressing SESN2 DCs markedly decreased apoptotic rates and attenuated HMGB1-induced ER morphology fragment together with inhibition of ERS-related protein translation. Furthermore, sesn2−/−-deficient mice manifested increased DC apoptosis and aggravated ERS extent in septic model. These results indicate that SESN2 appears to be a potential regulator to inhibit apoptotic ERS signaling that exerts a protective effect on apoptosis of DCs in the setting of septic challenge.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Trauma Research Center, Fourth Medical Center of the Chinese PLA General Hospital, Beijing, PR China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894); First Medical Center of the Chinese PLA General Hospital, Beijing, PR China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
2 Trauma Research Center, Fourth Medical Center of the Chinese PLA General Hospital, Beijing, PR China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
3 Department of Burns and Plastic Surgery, Guilin, PR China (GRID:grid.414252.4)
4 Trauma Research Center, Fourth Medical Center of the Chinese PLA General Hospital, Beijing, PR China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894); First Medical Center of the Chinese PLA General Hospital, Beijing, PR China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894); State Key Laboratory of Kidney Disease, the Chinese PLA General Hospital, Beijing, PR China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)